Igor Makhlin Dissecting Biologic Risk Using Genomic Assays - Implications for Extended Endocrine Therapy and Beyond , JAMA Network Open - In Press: 2024
Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A. Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights , JCO Oncol Pract: 2024
Makhlin I, Demissei BG, D'Agostino R, Hundley WG, Baleanu-Gogonea C, Wilcox NS, Chen A, Smith AM, O'Connell NS, Januzzi JL, Lesser GJ, Scherrer-Crosbie M, Ibáñez B, Tang WHW, Ky B. Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial , Clin Cancer Res, 30: 2024,2370-2376
Debashish Tripathy, Kashif Ali, Laila Agrawal, Sami M. Ali, Sibel Blau, Margaret Block, Michael A. Danso, Denise Yardley, Jay Andersen, Adrienne Gropper Waks, Priya Jayachandran, Igor Makhlin, Petros Nikolinakos, Richard Zuniga, Joyce O'Shaughnessy, Sandra Aung, Janice M. Lu, Kevin Kalinsky, William John Gradishar, Hope S. Rugo ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd) , Journal of Clinical Oncology, 42(16_suppl): 2024
A. DeMichele
A.S. Clark
L. Bayne
K. Rohn
I. Nivar
P. Wileyto
L. Berry
S. DeLuca
J. Savage
I. Makhlin
T.C. Pan
J. Graves
G. Belka
J. Wang
N. Shih
D. Berry
A. Nayak
M. Feldman
L. Chodosh 244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”) , ESMO Abstract, 34: 2023,S281
Fradley MG, Nguyen NHK, Madnick D, Chen Y, DeMichele A, Makhlin I, Dent S, Lefebvre B, Carver J, Upshaw JN, DeRemer D, Ky B, Guha A, Gong Y. Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer , J Am Heart Assoc, 12: 2023,e029361
Chen S, Paul MR, Sterner CJ, Belka GK, Wang D, Xu P, Sreekumar A, Pan TC, Pant DK, Makhlin I, DeMichele A, Mesaros C, Chodosh LA. PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies , Breast Cancer Res, 25(1): 2023,1
Kaufmann T, Chang P, Rosenberg SM, Frank E, Hobbs B, Bayne LJ, Nivar I, Goodspeed BL, Rohn KM, Kugler EM, Fox K, Domchek SM, Bradbury A, Shah PD, Knollman h, Jankowitz RC, Makhlin I, Clark AS, Chodosh LA, DeMichele A, Goodfellow KE. P5-08-01: Pilot study of a patient-reported outcome (PRO) measurement strategy to determine impact of screening for minimal residual disease (MRD) in high-risk breast cancer survivors , San Antonio Breast Cancer Symposium 2022, San Antonio, TX.: 2022
Makhlin I, McAndrew NP, Wileyto EP, Clark AS, Holmes R, Bottalico LN, Mesaros C, Blair IA, Jeschke GR, Fox KR, Domchek SM, Matro JM, Bradbury AR, Feldman MD, Hexner EO, Bromberg JF, DeMichele A. Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer , NPJ Breast Cancer, 8(1): 2022,122
Makhlin I, Korhonen KE, Martin ML, Gillman J, Schubert E, Pantel AR, Mankoff DA, Clark AS. (18)F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer , Radiol Imaging Cancer, 4(6): 2022
